DNA-based diagnostics provider Cancer Genetics, Inc., (CGI) and Roche Servicios S.A., an affiliate of Swiss drug maker Roche, have entered into an exclusive multiyear agreement to expand molecular diagnostic cancer testing in Central America and the Caribbean. Under the terms of the three-year contract agreement, CGI will leverage the power of Roche’s FDA-approved cobas platform as it seeks to become a center of excellence for oncology-focused testing in the region. Roche’s cobas technology allows for the amplification and sequencing of targeted genomic regions of interest, using mutational status to guide appropriate treatment selection.
Additionally, under the agreement, CGI will be the exclusive provider of molecular diagnostic cancer testing for Roche Servicios in Central America and the Caribbean. This expanded relationship covers multiple disease categories, including testing for lung cancer, breast cancer, and lymphoma. CGI first began offering such testing for Roche Servicios in late 2012.
CGI will initially focus on cobas-based testing starting with the FDA-approved epidermal growth factor receptor (EGRF) mutation test, intended to help select non-small cell lung cancer patients for treatment with EGFR inhibitors. The partnership allows for expansion into other cancer categories and regions as mutually decided by CGI and Roche. Learn more about the cobas product family.
